Connection

Graham Warren to Disease Progression

Back to Details
This is a "connection" page, showing publications Graham Warren has written about Disease Progression.
Graham Warren
Connection Strength
0.046
Disease Progression
  1. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol. 2017 Sep; 80(3):497-505.
    View in: PubMed
    Score: 0.027
  2. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck. 2013 May; 35(5):684-8.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.